https://www.azonano.com/news.aspx?newsID=41596&utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=arthritis_newsletter_21_december_2025
Researchers have developed a nanozyme-integrated hydrogel that directly targets advanced glycation end products (AGEs), a key driver of diabetic osteoarthritis (DOA).
No hay comentarios:
Publicar un comentario